法瑟姆制药
PHAT
6.92
-0.58
-7.73%
法瑟姆制药
US · PHAT
#3684 按市值排名
上市于 2019
6.92
-0.58
-7.73%
实时 - 追踪5344个代码 - 心跳于501秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例下降了2.8个百分点。
机构持股
- 机构持股比例
- 90.99% -2.81pp
- 机构数量
- 195 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund38.92%
VC/PE Fund34.47%
Hedge Fund13.82%
Individual/Insider3.51%
Public Company2.74%
Private Company0.54%
Government Pension Fund0.21%
Insurance Company0.19%
Other5.52%
主要股东 截至 2026-06-30
Frazier Life Sciences Management, LP
15.41% · 12.47M 股
Medicxi Ventures (UK) LLP
9.23% · 7.46M 股
BlackRock
5.59% · 4.53M 股
Invesco Ltd.
4.98% · 4.03M 股
Abingworth LLP
4.32% · 3.50M 股
Millennium Management LLC
4.17% · 3.38M 股
Vanguard Capital Management, LLC
3.72% · 3.01M 股
GW&K Investment Management, LLC
2.68% · 2.17M 股
Franklin Resources
2.44% · 1.97M 股
New Enterprise Associates, Inc.
2.42% · 1.96M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 32次买入 · 18次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Frazier Life Sciences Management, LP | -- | 15.41% |
| David Socks | Co-Founder | 1.51% |
| Azmi Nabulsi | Co-Founder & COO | 0.98% |
| Terrie Curran | Chief Executive Officer | 0.48% |
| Asit Parikh | Independent Director | 0.18% |
| Robert Breedlove | -- | 0.08% |
| Molly Henderson | Chief Financial & Business Officer | 0.08% |
| Frank Karbe | Independent Director | 0.07% |
| James Topper | Independent Director | 0.05% |
| Heidi Fields | Independent Director | 0.02% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-02 | Robert Breedlove | -- | Sale to Issuer | -460 | $9.05 |
| 2026-07-13 | Robert Breedlove | -- | Sale to Issuer | -1,555 | $11.04 |
| 2026-05-21 | Asit Parikh | Independent Director | Other Acquisition | +28,000 | -- |
| 2026-05-21 | Asit Parikh | Independent Director | Other Disposition | -28,000 | -- |
| 2026-05-19 | Asit Parikh | Independent Director | Derivative Sale to Issuer | -17,500 | -- |
| 2026-05-19 | Asit Parikh | Independent Director | Derivative Exercise and Retained | +17,500 | $4.95 |
| 2026-05-18 | Michael Cola | Independent Interim Chairman of the Board | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Heidi Fields | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | James Topper | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Frank Karbe | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Theodore Schroeder | Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Asit Parikh | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-05-18 | Mark Stenhouse | Independent Director | Other Acquisition | +24,122 | -- |
| 2026-03-09 | Asit Parikh | Independent Director | Other Acquisition | +40,000 | -- |
| 2026-03-09 | Asit Parikh | Independent Director | Other Disposition | -40,000 | -- |
| 2026-02-26 | Robert Breedlove | -- | Sale to Issuer | -1,378 | $12.56 |
| 2026-02-26 | Robert Breedlove | -- | Other Acquisition | +2,790 | -- |
| 2026-02-26 | Robert Breedlove | -- | Other Acquisition | +13,000 | -- |
| 2026-02-09 | Steven Basta | Chief Executive Officer | Sale to Issuer | -6,277 | $12.82 |
| 2026-02-09 | Steven Basta | Chief Executive Officer | Other Acquisition | +12,362 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
法瑟姆制药 讨论区 0 条评论